The company achieved a turnaround with net income of $87,000 for 2024 compared to a net loss of $251,500 in 2023, driven by increased distributor and website sales with total revenues of $1,844,966 in 2024 versus $597,595 in 2023. Nowtransit has filed several patent applications for its Methylene Blue products and is exploring potential partnerships and strategic alliances to capitalize on these patents.
Cyborg Score Rationale
The company has identified material weaknesses in internal controls, lacks a proven track record of profitability, and faces substantial doubt about its ability to continue as a going concern. While revenue growth is encouraging, the company's early-stage status and going concern issues present significant risks.
Top Insights
Recent profitability inflection: First net income year in 2024 ($87K) following three years of losses, with revenue growing 209% YoY
Patent-protected product pipeline: Multiple patent applications for methylene blue formulations targeting neurocognitive and metabolic health markets
Multi-channel distribution strategy: Leveraging distributor networks, website, private label, and direct sales channels
Going concern warning: Material weaknesses in internal controls and heavy reliance on related-party advances raises long-term viability questions
Named Competitors
Optimized Health Solutions — Brain health and cognitive wellness supplements
Thorne — Clinical-grade health supplements
Vitacost — Online health and wellness retail platform
Recent Developments
(March 2025) Form 10-K filing shows $87K net income for fiscal year 2024 compared to prior-year loss
(2024) Completed $1,000,000 private placement with accredited investors
(2024) Filed patent applications for NeuroPro Plus, ADHD 365, and other methylene blue formulations
Open the full interactive Nowtransit Inc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.